A Flu Vaccine With 30 Percent Effectiveness Still Prevents Tens of Thousands of Hospitalizations. Here Is Why That Math Matters.

The CDC has just published interim data on this season’s flu vaccine, and the numbers are likely to be misread. Among children and adolescents, vaccine effectiveness against outpatient visits ranged from 38 to 41 percent. Among adults, it ranged from 22 to 34 percent. Those figures will be cited by some as evidence that the flu shot does not work, or that it works so poorly as to make the annual ritual of vaccination pointless. That conclusion misunderstands both the biology of influenza and the arithmetic of population health.

Why this year’s effectiveness numbers look the way they do

Influenza is unlike most of the pathogens against which we vaccinate. Measles is essentially the same virus today that it was when the vaccine was developed in the 1960s, which is why a single childhood series confers lifelong protection. Influenza is the opposite. The virus mutates rapidly, and the vaccine has to be redesigned every year based on the strains scientists predict will circulate during the coming season. When the prediction is good, effectiveness is high. When the prediction is off, effectiveness falls.

This year, the dominant circulating strain, influenza A(H3N2) subclade K, emerged after the season’s vaccine was already selected. That mismatch predictably lowered effectiveness, in exactly the way you would expect when the target moves after the arrow has been loosed. The interim numbers reflect that mismatch, and they should be understood as a property of this particular year, not as a verdict on the flu vaccine as a tool.

The arithmetic of partial protection

One of the most important axioms in public health is that a small number multiplied by a very big number is a big number. A vaccine that is 30 percent effective sounds underwhelming when described in percentage terms. The same vaccine, applied to a population in which tens of millions of people are infected each year, prevents an enormous absolute amount of suffering. During the 2022-23 flu season, when overall vaccine effectiveness was also around 30 percent, the flu shot still prevented an estimated 71,000 hospitalizations and 4,300 deaths in the United States. Those are not theoretical numbers. They are people who would have ended up in an emergency room, or in an ICU bed, or in a morgue, and who did not, because tens of millions of their neighbors got vaccinated and reduced the amount of virus circulating in the population.

This is what makes vaccines such powerful public health tools, and it is why they occupy the middle tier of the health impact pyramid. A single encounter with the health system produces durable protection that does not require any further effort from the person who received it. Even partial protection, scaled across a population, produces enormous absolute benefit. The math runs the other way too: a small percentage of people declining the vaccine, multiplied by the size of the population, produces a small but real increase in transmission, hospitalization, and death.

The wrong question and the right one

The way the public conversation about flu vaccines usually proceeds is to ask whether this year’s shot is “good” or “bad,” and to make individual vaccination decisions on the basis of that judgment. That framing collapses two different questions into one. The first question, whether the shot will completely prevent you from getting the flu, has always had the same answer: probably not, and certainly not in a season with a strain mismatch. The second question, whether the shot meaningfully reduces your risk of being hospitalized or killed by influenza and reduces the risk that you will transmit the virus to someone more vulnerable, has a different answer, and the answer is yes.

The interim data this season are a good reminder that the flu vaccine is not magic. It is a tool that works imperfectly against a moving target, and its effectiveness will vary from year to year in ways that have less to do with the vaccine itself than with the unpredictability of viral evolution. The case for getting it does not depend on the vaccine being perfect. It depends on the same logic that justifies every population-level intervention: that small reductions in risk, multiplied across enough people, produce results that are anything but small.

This logic, that the size of a population can transform a modest individual benefit into an enormous collective one, is the same reasoning that justifies careful use of antibiotics, restraint in prescribing, and every other public health intervention that asks individuals to do something whose value is most visible when you zoom out from the individual to the population. The flu vaccine is one of the clearest examples we have. Thirty percent effectiveness, applied to seventy million people, is not a failure. It is the difference between a season we get through and a season that overwhelms the hospital system.

Related FAQs

These related FAQs explain why vaccine effectiveness, population protection, and changing immunity matter for flu-season planning.

• How do mutation rates of a virus, such as with influenza, affect the stability of herd immunity?
• What are the implications of waning immunity for booster vaccination campaigns?
• How do vaccines contribute to the concept of herd immunity, and why is this important for community health?
• What measures are in place to monitor the safety and efficacy of vaccines post-implementation of new guidelines?